CN115814054A - Skin care composition, skin care product and application thereof - Google Patents
Skin care composition, skin care product and application thereof Download PDFInfo
- Publication number
- CN115814054A CN115814054A CN202211078137.XA CN202211078137A CN115814054A CN 115814054 A CN115814054 A CN 115814054A CN 202211078137 A CN202211078137 A CN 202211078137A CN 115814054 A CN115814054 A CN 115814054A
- Authority
- CN
- China
- Prior art keywords
- skin care
- hyaluronic acid
- salt
- care composition
- molecular weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 102
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims abstract description 76
- 229920002674 hyaluronan Polymers 0.000 claims abstract description 76
- 229960003160 hyaluronic acid Drugs 0.000 claims abstract description 76
- 150000003839 salts Chemical class 0.000 claims abstract description 68
- KNFLNGRLKALWRF-LDXSYGEZSA-N CSCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(N)=O)CC1=CC=CC=C1 Chemical compound CSCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(N)=O)CC1=CC=CC=C1 KNFLNGRLKALWRF-LDXSYGEZSA-N 0.000 claims abstract description 32
- SSISHJJTAXXQAX-ZETCQYMHSA-N L-ergothioneine Chemical compound C[N+](C)(C)[C@H](C([O-])=O)CC1=CNC(=S)N1 SSISHJJTAXXQAX-ZETCQYMHSA-N 0.000 claims abstract description 32
- 229940093497 ergothioneine Drugs 0.000 claims abstract description 32
- 230000019612 pigmentation Effects 0.000 claims abstract description 11
- 206010061218 Inflammation Diseases 0.000 claims abstract description 6
- 239000002537 cosmetic Substances 0.000 claims abstract description 4
- 239000003814 drug Substances 0.000 claims abstract description 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 5
- 239000011593 sulfur Substances 0.000 claims description 5
- 229910052717 sulfur Inorganic materials 0.000 claims description 5
- 230000037390 scarring Effects 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 abstract description 20
- 230000008439 repair process Effects 0.000 abstract description 12
- 208000012641 Pigmentation disease Diseases 0.000 abstract description 11
- 208000002874 Acne Vulgaris Diseases 0.000 abstract description 9
- 206010000496 acne Diseases 0.000 abstract description 9
- 206010052428 Wound Diseases 0.000 abstract description 8
- 208000027418 Wounds and injury Diseases 0.000 abstract description 8
- 230000000694 effects Effects 0.000 abstract description 7
- 230000035876 healing Effects 0.000 abstract description 5
- 230000004054 inflammatory process Effects 0.000 abstract description 4
- 231100000241 scar Toxicity 0.000 abstract description 3
- 208000032544 Cicatrix Diseases 0.000 abstract description 2
- 208000034656 Contusions Diseases 0.000 abstract description 2
- 230000004888 barrier function Effects 0.000 abstract description 2
- 230000001684 chronic effect Effects 0.000 abstract description 2
- 230000000474 nursing effect Effects 0.000 abstract description 2
- 239000011241 protective layer Substances 0.000 abstract description 2
- 230000009467 reduction Effects 0.000 abstract description 2
- 230000036573 scar formation Effects 0.000 abstract description 2
- 230000037387 scars Effects 0.000 abstract description 2
- 230000037307 sensitive skin Effects 0.000 abstract description 2
- 208000020154 Acnes Diseases 0.000 abstract 1
- 238000009098 adjuvant therapy Methods 0.000 abstract 1
- 239000006071 cream Substances 0.000 abstract 1
- 230000003467 diminishing effect Effects 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 230000002093 peripheral effect Effects 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 109
- 229920002385 Sodium hyaluronate Polymers 0.000 description 35
- 229940010747 sodium hyaluronate Drugs 0.000 description 35
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 35
- 230000000052 comparative effect Effects 0.000 description 21
- 238000003756 stirring Methods 0.000 description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 239000000126 substance Substances 0.000 description 11
- 239000003755 preservative agent Substances 0.000 description 8
- 230000002335 preservative effect Effects 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 239000000463 material Substances 0.000 description 7
- 239000002562 thickening agent Substances 0.000 description 7
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 230000002757 inflammatory effect Effects 0.000 description 5
- 102000008314 Type 1 Melanocortin Receptor Human genes 0.000 description 4
- 108010021428 Type 1 Melanocortin Receptor Proteins 0.000 description 4
- 230000032683 aging Effects 0.000 description 4
- 229940024606 amino acid Drugs 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 230000008591 skin barrier function Effects 0.000 description 4
- 230000002195 synergetic effect Effects 0.000 description 4
- WCDDVEOXEIYWFB-VXORFPGASA-N (2s,3s,4r,5r,6r)-3-[(2s,3r,5s,6r)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O)[C@H](O)[C@H]1O WCDDVEOXEIYWFB-VXORFPGASA-N 0.000 description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 229920002125 Sokalan® Polymers 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 230000000975 bioactive effect Effects 0.000 description 3
- 229960001631 carbomer Drugs 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 229940014041 hyaluronate Drugs 0.000 description 3
- WXSLOYPZKHFWII-UHFFFAOYSA-N propyl 4-hydroxybenzoate;sodium Chemical compound [Na].CCCOC(=O)C1=CC=C(O)C=C1 WXSLOYPZKHFWII-UHFFFAOYSA-N 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 235000010226 sodium ethyl p-hydroxybenzoate Nutrition 0.000 description 3
- 239000004402 sodium ethyl p-hydroxybenzoate Substances 0.000 description 3
- 235000010230 sodium propyl p-hydroxybenzoate Nutrition 0.000 description 3
- 239000004404 sodium propyl p-hydroxybenzoate Substances 0.000 description 3
- QYNMSPKSYXPZHG-UHFFFAOYSA-M sodium;4-ethoxycarbonylphenolate Chemical compound [Na+].CCOC(=O)C1=CC=C([O-])C=C1 QYNMSPKSYXPZHG-UHFFFAOYSA-M 0.000 description 3
- 230000029663 wound healing Effects 0.000 description 3
- RBCOYOYDYNXAFA-UHFFFAOYSA-L (5-hydroxy-4,6-dimethylpyridin-3-yl)methyl phosphate Chemical compound CC1=NC=C(COP([O-])([O-])=O)C(C)=C1O RBCOYOYDYNXAFA-UHFFFAOYSA-L 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 229920002683 Glycosaminoglycan Polymers 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 239000000637 Melanocyte-Stimulating Hormone Substances 0.000 description 2
- 108010007013 Melanocyte-Stimulating Hormones Proteins 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 230000003592 biomimetic effect Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 210000000245 forearm Anatomy 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000005808 skin problem Effects 0.000 description 2
- 210000000434 stratum corneum Anatomy 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
- KIUKXJAPPMFGSW-YXBJCWEESA-N (2s,4s,5r,6s)-6-[(2s,3r,5s,6r)-3-acetamido-2-[(3s,4r,5r,6r)-6-[(3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@@H]3[C@@H]([C@@H](O)C(O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)C(C(O)=O)O1 KIUKXJAPPMFGSW-YXBJCWEESA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical group OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- BVHLGVCQOALMSV-JEDNCBNOSA-N L-lysine hydrochloride Chemical compound Cl.NCCCC[C@H](N)C(O)=O BVHLGVCQOALMSV-JEDNCBNOSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- 102000005348 Neuraminidase Human genes 0.000 description 1
- 108010006232 Neuraminidase Proteins 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 206010042209 Stress Diseases 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 102000003425 Tyrosinase Human genes 0.000 description 1
- 108060008724 Tyrosinase Proteins 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- JAWMENYCRQKKJY-UHFFFAOYSA-N [3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-ylmethyl)-1-oxa-2,8-diazaspiro[4.5]dec-2-en-8-yl]-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]methanone Chemical compound N1N=NC=2CN(CCC=21)CC1=NOC2(C1)CCN(CC2)C(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F JAWMENYCRQKKJY-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000002390 adhesive tape Substances 0.000 description 1
- 230000000240 adjuvant effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- -1 antiseptic Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 238000005282 brightening Methods 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 125000000600 disaccharide group Chemical group 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 210000003701 histiocyte Anatomy 0.000 description 1
- VJVOFLWZDWLHNR-MRCUWXFGSA-N icosan-9-yl (z)-docos-13-enoate Chemical compound CCCCCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCCCCC\C=C/CCCCCCCC VJVOFLWZDWLHNR-MRCUWXFGSA-N 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 102000009634 interleukin-1 receptor antagonist activity proteins Human genes 0.000 description 1
- 108040001669 interleukin-1 receptor antagonist activity proteins Proteins 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229960005337 lysine hydrochloride Drugs 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 230000008099 melanin synthesis Effects 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 230000037323 metabolic rate Effects 0.000 description 1
- KRCMKUNIILUXPF-UHFFFAOYSA-N methyl 4-hydroxybenzoate;sodium Chemical compound [Na].COC(=O)C1=CC=C(O)C=C1 KRCMKUNIILUXPF-UHFFFAOYSA-N 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 230000036559 skin health Effects 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 235000010268 sodium methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004290 sodium methyl p-hydroxybenzoate Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000037072 sun protection Effects 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
Abstract
The present application provides a skin care composition comprising: hyaluronic acid or its salt, ergothioneine, and nonapeptide-1. This application plays the physical barrier effect through forming the protective layer on the surface of the wound. Can be used for nursing non-chronic wound surfaces such as small wounds, bruises, cut wounds and the like and peripheral skin. Meanwhile, the acne cream is suitable for repairing the skin after the healing of mild and moderate acnes; has adjuvant treatment effect on sensitive skin and early pigmentation after laser photon treatment and scar formation reduction, and can effectively shorten the repair time after laser photon treatment. In addition, the application also provides the use of the skin care composition in the preparation of medicines or cosmetics for diminishing inflammation, reducing pigmentation and superficial scars.
Description
Technical Field
The application relates to the technical field of skin care, in particular to a skin care composition, a skin care product and application thereof.
Background
Because normal aging of human is an irresistible natural process, physiological changes in the aging process of human body are mainly reflected in the loss of organism histiocytes and constitutional substances, the slowing of organism metabolic rate and the decline of organism and organ functions, and finally skin problems such as uneven skin color, dullness, color spots and the like are generated. Senescence is inevitable, but can be delayed. Keeping the moisture content of the skin and continuously supplementing the nutrient substances of the skin are one of the important measures for delaying the aging. Meanwhile, many teenagers in adolescence face skin blain, so that mild and moderate acne is formed and is poor after healing, and the skin is damaged. How to reduce the influence of mild and moderate acne on teenagers by using bioactive materials is the current important research subject direction. With the rapid development of science and technology, the living standard of people is continuously improved, and young people often select laser photon skin tendering to manage the skin aiming at the skin problem. Although the laser photon skin tendering operation can effectively treat dark skin color, improve pores and the like, attention needs to be paid to sun protection after operation, pigmentation at the early stage after operation, infection after skin barrier breakage and the like. How to effectively relieve the stress symptom after the laser photon skin tendering operation is also one of the important topics which need to be researched urgently.
Hyaluronic acid or a salt thereof is a linear mucopolysaccharide consisting of repeated linkages of N-acetylglucosamine and disaccharide units of glucuronic acid. Hyaluronic acid or a salt thereof, which is a physiologically essential substance of the human body, is widely present in various tissues of the human body, is also an important component of extracellular matrix, and has excellent moisture retention as well as anti-inflammatory and wound healing promoting properties. Hyaluronic acid or its salt has different molecular weights, and hyaluronic acid or its salt with high molecular weight can inhibit inflammation and promote cell migration, and hyaluronic acid or its salt with low molecular weight can promote cell proliferation and promote wound healing. Ergothioneine is a natural antioxidant, is a unique cell physiological protective agent, and has multiple physiological functions of scavenging free radicals, whitening skin, resisting aging, preventing ultraviolet radiation damage, maintaining DNA synthesis and normal cell growth, and the like. Nonapeptide-1 is a biomimetic peptide, which has a very good match with MC1 receptor, and thus can be used as an antagonist of melanocyte stimulating hormone to competitively bind with MC1 receptor. Therefore, further activation of the neuraminidase, which leads to melanin production, can be prevented.
How to find a simple, convenient, safe and effective use mode, different bioactive materials are compounded to achieve the synergistic effect, and then the research direction becomes important for relieving skin aging, brightening pigmentation skin color, promoting mild and moderate acne healing and effectively shortening the laser photon postoperative repair time.
Disclosure of Invention
In order to solve the technical problems in the prior art, the application provides a skin care composition, a skin care product and application thereof.
The technical scheme of the application is as follows:
1. a skin care composition, comprising: hyaluronic acid or its salt, ergothioneine, and nonapeptide-1.
2. The skin care composition according to item 1,
the hyaluronic acid or the salt thereof is composed of high molecular weight hyaluronic acid or the salt thereof, and low molecular weight hyaluronic acid or the salt thereof,
wherein the molecular weight of the high molecular weight hyaluronic acid or salt thereof is 1000-1500kDa, and the molecular weight of the low molecular weight hyaluronic acid or salt thereof is 200-700kDa.
3. The skin care composition according to item 2, wherein the mass ratio of the high molecular weight hyaluronic acid or salt thereof to the low molecular weight hyaluronic acid or salt thereof is 1.
4. The skin care composition according to item 1,
0.05-1.0wt% of hyaluronic acid or salt thereof, 0.001-0.3 wt% of ergot sulfur, and 0.01-0.1 wt% of nonapeptide-1, based on the total weight of the skin care composition;
preferably, the hyaluronic acid or the salt thereof is 0.1-0.5wt%, the ergot sulfur is 0.005-0.2 wt%, and the nonapeptide-1 is 0.01-0.05 wt%.
5. The skin care composition of item 1, further comprising a functional material, preferably, the functional material is 0.01-2.0wt% based on the total weight of the skin care composition.
6. The skin care composition according to item 1, further comprising a preservative, preferably, the preservative is 0.01-0.5wt% based on the total weight of the skin care composition.
7. The skin care composition of item 1, further comprising a thickener, preferably, 0.01 to 2.0wt% based on the total weight of the skin care composition.
8. A skin care product comprising the skin care composition of any one of items 1-7.
9. Use of the skin care composition of any one of claims 1-7 or the skin care product of claim 8 in the manufacture of a medicament or cosmetic for anti-inflammation, reducing pigmentation, and superficial scarring.
Compared with the prior art, the technical effect of this application:
(1) Hyaluronic acid or its salt is a natural high molecular linear mucopolysaccharide, widely exists in animal tissues and body fluids, and has good biocompatibility. The application utilizes the excellent moisture retention and bacteriostasis of the hyaluronic acid and the characteristics of promoting wound healing to reduce the water loss of the skin and repair the damaged skin barrier, successfully explores the effect of the hyaluronic acid or the salt thereof with different molecular weights on protecting the skin and provides a proper molecular weight adding range.
(2) The skin care composition containing hyaluronic acid or salt thereof comprises hyaluronic acid or salt thereof, ergothioneine and nonapeptide-1, the three main components are combined, the defect of single function of bioactive materials is overcome, the compounded hyaluronic acid or salt thereof, ergothioneine and nonapeptide-1 can be synergized, pigmentation and deposition are effectively prevented, high-efficiency antioxidation is realized, the healing effect of mild and moderate acne damaged skin is improved, meanwhile, the skin care composition has an anti-inflammatory effect, and the skin repair process is accelerated.
Detailed Description
The present application is described in detail below with reference to the described embodiments, however, it should be understood that the present application may be embodied in various forms and should not be limited by the embodiments set forth herein. Rather, these embodiments are provided so that this disclosure will be thorough and complete, and will fully convey the scope of the disclosure to those skilled in the art.
It should be noted that certain terms are used throughout the description and claims to refer to particular components. As one skilled in the art will appreciate, various names may be used to refer to a component. This specification and claims do not intend to distinguish between components that differ in name but not function. In the following description and in the claims, the terms "include" and "comprise" are used in an open-ended fashion, and thus should be interpreted to mean "include, but not limited to. The description that follows is a preferred embodiment of the present application, but is made merely for the purpose of illustrating the general principles of the application and not for the purpose of limiting the scope of the application. The protection scope of the present application shall be subject to the definitions of the appended claims.
The present application provides a skin care composition comprising hyaluronic acid or a salt thereof, the skin care composition comprising: hyaluronic acid or a salt thereof, ergothioneine, and nonapeptide-1.
The hyaluronate can be sodium hyaluronate, zinc hyaluronate, magnesium hyaluronate, calcium hyaluronate, etc. The hyaluronic acid or the salt thereof of the present application may be hyaluronic acid or the salt thereof having a single molecular weight range, or may be composed of several kinds of hyaluronic acid or the salt thereof having different molecular weights.
In a specific embodiment, the hyaluronic acid or salt thereof consists of high molecular weight hyaluronic acid or salt thereof having a molecular weight of 1000-1500kDa, such as 1000kDa, 1050kDa, 1100kDa, 1150kDa, 1200kDa, 1250kDa, 1300kDa, 1350kDa, 1400kDa, 1450kDa, 1500kDa, and low molecular weight hyaluronic acid or salt thereof having a molecular weight of 200-700kDa, such as 2200kDa, 250kDa, 300kDa, 350kDa, 400kDa, 450kDa, 500kDa, 550kDa, 600kDa, 650kDa, 700kDa, or salt thereof.
The high molecular weight hyaluronic acid or salt thereof and the low molecular weight hyaluronic acid or salt thereof may be present in any mass ratio. In a specific embodiment, the mass ratio of the high molecular weight hyaluronic acid or salt thereof to the low molecular weight hyaluronic acid or salt thereof is 1.1 to 2, and may be, for example, 1.1, 1.5, 1:1, 1.5, 1:2, preferably 1.5 to 1.5, and more preferably 1:1.
Ergothioneine is a natural amino acid which is present in a plurality of animals and plants and is rich in content, cannot be synthesized by animal organisms, can be taken in only from food, and belongs to rare amino acid. Ergothioneine plays a unique role in the synthesis process of body cells and has strong oxidation resistance.
Nonapeptide-1 is a biomimetic peptide, has a good matching property with MC1 receptor on melanocyte, and can be used as an antagonist of melanocyte stimulating hormone to competitively bind with MC1 receptor and prevent tyrosinase from being further activated to generate melanin.
In some embodiments of the present application, the skin care composition consists of hyaluronic acid or a salt thereof, ergothioneine, and nonapeptide-1.
In some embodiments of the present application, the mass ratio of the hyaluronic acid or salt thereof, ergothioneine, nonapeptide-1 is (0.05-1.0): (0.001-0.3): 0.01-0.1), for example, the mass ratio of the hyaluronic acid or salt thereof, ergothioneine, nonapeptide-1 may be 0.05:0.001:0.01, 0.1:0.005:0.02, 0.2:0.01:0.03, 0.3:0.02:0.04, 0.4:0.03:0.05, 0.5:0.05:0.05, 0.6:0.07:0.06, 0.7:0.1:0.07, 0.8:0.2:0.09, 1.0:0.3:0.1, 0.05:0.001:0.1, 1.0:0.001:0.1 or any range therebetween;
in some embodiments of the present application, the hyaluronic acid or salt thereof is 0.05-1.0wt%, the ergothioneine is 0.001-0.3 wt%, the nonapeptide-1 is 0.01-0.1 wt%, based on the total weight of the skin care composition;
preferably, the hyaluronic acid or the salt thereof is 0.1-0.5wt%, the ergot sulfur is 0.005-0.2 wt%, and the nonapeptide-1 is 0.01-0.05 wt%.
For example, the hyaluronic acid or salt thereof can be 0.05wt%, 0.1wt%, 0.15wt%, 0.2wt%, 0.25wt%, 0.3wt%, 0.35wt%, 0.4wt%, 0.45wt%, 0.5wt%, 0.55wt%, 0.6wt%, 0.65wt%, 0.7wt%, 0.75wt%, 0.8wt%, 0.85wt%, 0.9wt%, 0.95wt%, 1.0wt%, or any range therebetween, based on the total weight of the skin care composition;
the ergothioneine can be 0.001wt%, 0.002wt%, 0.003wt%, 0.004wt%, 0.005wt%, 0.006wt%, 0.007wt%, 0.008wt%, 0.009wt%, 0.01wt%, 0.02wt%, 0.03wt%, 0.04wt%, 0.05wt%, 0.06wt%, 0.07wt%, 0.08wt%, 0.09wt%, 0.1wt%, 0.15wt%, 0.2wt%, 0.25wt%, 0.3wt%, or any range therebetween.
The nonapeptide-1 can be 0.01wt%, 0.02wt%, 0.03wt%, 0.04wt%, 0.05wt%, 0.06wt%, 0.07wt%, 0.08wt%, 0.09wt%, 0.1wt%, or any range therebetween.
The present application also provides a skin care product comprising the above skin care composition.
In some embodiments of the present application, the skin care composition or skin care product further comprises a functional material.
The functional substance is 0.01 to 2.0wt%, preferably 0.05 to 1.5wt%, further preferably 0.05 to 0.5wt%, for example, the functional substance can be 0.01wt%, 0.05wt%, 0.1wt%, 0.15wt%, 0.2wt%, 0.25wt%, 0.3wt%, 0.35wt%, 0.4wt%, 0.45wt%, 0.5wt%, 0.55wt%, 0.6wt%, 0.65wt%, 0.7wt%, 0.75wt%, 0.8wt%, 0.85wt%, 0.9wt%, 0.95wt%, 1.0wt%, 1.05wt%, 1.1wt%, 1.15wt%, 1.2wt%, 1.25wt%, 1.3wt%, 1.35wt%, 1.4wt%, 1.45wt%, 1.5wt%, 1.55wt%, 1.6wt%, 1.65wt%, 1.7wt%, 1.75wt%, 1.8wt%, 1.85wt%, 1.9wt%, 1.95wt%, 2.0wt%, or any range therebetween.
Wherein the functional substance comprises an amino acid and/or a vitamin. Wherein the amino acid is one or more than two selected from leucine, isoleucine, valine, glycine, proline, lysine hydrochloride, arginine, threonine and gamma-aminobutyric acid, and the vitamin is one or more than two selected from B vitamins and vitamin C.
In some embodiments of the present application, the skin care composition or skin care product further comprises a thickener in an amount of 0.01 to 2.0wt%, preferably 0.05 to 1.0wt%, and more preferably 0.05 to 0.15wt%, based on the total weight of the skin care composition or skin care product, for example, the thickener can be 0.01wt%, 0.05wt%, 0.1wt%, 0.15wt%, 0.2wt%, 0.25wt%, 0.3wt%, 0.35wt%, 0.4wt%, 0.45wt%, 0.5wt%, 0.55wt%, 0.6wt%, 0.65wt%, 0.7wt%, 0.75wt%, 0.8wt%, 0.85wt%, 0.9wt%, 0.95wt%, 1.0wt%, 1.05wt%, 1.1wt%, 1.15wt%, 1.2wt%, 1.25wt%, 1.3wt%, 1.35wt%, 1.4wt%, 1.95wt%, 1.0.0 wt%, 1.5wt%, 1.95wt%, 1.5wt%, 1.1.1.1 wt%, 1.95wt%, 1.5wt%, or any range therebetween.
Wherein the thickening agent is selected from one or more than two of sodium carboxymethylcellulose, carbomer and guar gum.
In some embodiments of the present application, the skin care composition or skin care product further comprises a preservative in an amount of 0.01 to 0.5wt%, preferably 0.05 to 0.5wt%, and more preferably 0.05 to 0.2wt%, based on the total weight of the skin care composition or skin care product, for example, the preservative may be 0.01wt%, 0.05wt%, 0.1wt%, 0.15wt%, 0.2wt%, 0.25wt%, 0.3wt%, 0.35wt%, 0.4wt%, 0.45wt%, 0.5wt%, or any range therebetween.
Wherein the preservative is selected from one or more of sodium methyl p-hydroxybenzoate, sodium ethyl p-hydroxybenzoate and sodium propyl p-hydroxybenzoate.
In a particular example, the skin care composition of the present application consists of hyaluronic acid or a salt thereof, ergothioneine, nonapeptide-1, a functional substance, a preservative, a thickener, and water. Wherein the contents of hyaluronic acid or its salt, ergothioneine, nonapeptide-1, functional substance, antiseptic, and thickener are as described above, and the balance is water.
In one particular example, a method of preparing a skin care composition comprising hyaluronic acid or a salt thereof, comprises the steps of:
adding hyaluronic acid or its salt, ergothioneine, and functional substance into water, and stirring to obtain skin care composition containing hyaluronic acid or its salt.
In one particular example, a method of preparing a skin care composition comprising hyaluronic acid or a salt thereof, comprises the steps of:
fully stirring the preservative and water, and standing after the preservative is dissolved to obtain a mixture A;
adding hyaluronic acid or its salt, ergothioneine, and functional substance into the mixture A, and stirring to obtain mixture B;
adding thickener into the mixture B, stirring, and standing to obtain skin care composition containing hyaluronic acid or its salt.
In some embodiments of the present application, a method of preparing a skin care composition comprising hyaluronic acid or a salt thereof, comprises the steps of:
fully stirring sodium ethyl p-hydroxybenzoate, sodium propyl p-hydroxybenzoate and water, and standing to obtain a mixture A;
mixing hyaluronic acid or its salt, ergothioneine, nonapeptide-1, glycine, and vitamin B 6 Adding into the mixture A, and stirring for 6h to uniform state to obtain mixture B;
adding carbomer into the mixture B, stirring, and standing to obtain skin care composition containing hyaluronic acid or its salt.
In some embodiments of the present application, a method of preparing a skin care composition comprising hyaluronic acid or a salt thereof, comprises the steps of:
fully stirring sodium ethyl p-hydroxybenzoate, sodium propyl p-hydroxybenzoate and water for injection, and standing to obtain mixture A;
mixing high molecular weight hyaluronic acid or its salt with molecular weight of 1000-1500kDa, low molecular weight hyaluronic acid or its salt with molecular weight of 200-700kDa, ergothioneine, nonapeptide-1, glycine, and vitamin B 6 Adding into the mixture A, and stirring for 6h to uniform state to obtain mixture B;
adding carbomer into the mixture B, stirring, and standing to obtain skin care composition containing hyaluronic acid or its salt.
In some embodiments of the present application, the skin care product is any one of a skin repair liquid, an application serum, or a skin spray.
The present application also provides the use of the above-mentioned skin care composition or skin care product for the preparation of a medicament or cosmetic for anti-inflammatory, reducing pigmentation and superficial scarring.
The skin care composition containing hyaluronic acid or salt thereof is added with three substances of sodium hyaluronate, ergothioneine and nonapeptide-1 at the same time, so that the composition has multiple functions:
1. can form a protective layer on the surface of the wound surface to play a role of physical barrier. The product is used for nursing non-chronic wounds such as small wounds, bruises and cut wounds and surrounding skin;
2. promoting the repair of the skin after the healing of mild and moderate acne;
3. has adjuvant effect on sensitive skin and early pigmentation after laser photon treatment and scar formation reduction;
4. effectively shorten the post-operation repair time of the laser photon.
The materials used in the tests and the test methods are generally and/or specifically described herein, and in the examples below,% means wt%, i.e. percent by weight, unless otherwise specified. The reagents or instruments used are not indicated by the manufacturer, and are all conventional reagent products commercially available, wherein Table 1 is a source of raw materials used in the examples.
Table 1 sources of raw materials used in the examples
| Raw materials | Manufacturer of the product |
| Hyaluronic acid sodium salt | BLOOMAGE BIOTECH Co.,Ltd. |
| Ergothioneine | BLOOMAGE BIOTECH Co.,Ltd. |
| Nonapeptide-1 | REALI TIDE BIOLOGICAL TECHNOLOGY (WEIHAI) Co.,Ltd. |
Example 1 preparation of skin Care compositions
Adding 0.05wt% of sodium hyaluronate with a molecular weight of 1200kDa, 0.05wt% of sodium hyaluronate with a molecular weight of 500kDa, 0.005wt% of ergothioneine and 0.001wt% of nonapeptide-1 into water based on the total weight of the skin care composition, and fully stirring for 6h to obtain a uniform state, thereby obtaining the skin care composition.
Example 2 preparation of skin Care compositions
Example 2 differs from example 1 only in that sodium hyaluronate with a molecular weight of 1200kDa was added in an amount of 0.25wt%, and sodium hyaluronate with a molecular weight of 500kDa was added in an amount of 0.25wt%, and the rest conditions were the same.
Example 3 preparation of skin Care compositions
Example 3 differs from example 1 only in that sodium hyaluronate with a molecular weight of 1200kDa was added in an amount of 0.025wt%, and sodium hyaluronate with a molecular weight of 500kDa was added in an amount of 0.025wt%, with the remaining conditions being the same.
Example 4 preparation of skin Care compositions
Example 4 differs from example 1 only in that sodium hyaluronate with a molecular weight of 1200kDa was added in an amount of 0.5wt% and sodium hyaluronate with a molecular weight of 500kDa was added in an amount of 0.5wt%, and the rest conditions were the same.
EXAMPLE 5 preparation of skin Care compositions
Example 5 differs from example 1 only in that ergothioneine was added in an amount of 0.001wt%, and the other conditions were the same.
EXAMPLE 6 preparation of skin Care compositions
Example 6 differs from example 1 only in that the ergothioneine addition was 0.2wt%, and the other conditions were the same.
Example 7 preparation of skin Care composition
Example 7 differs from example 1 only in that the ergothioneine addition was 0.3wt%, and the other conditions were the same.
EXAMPLE 8 preparation of skin Care compositions
Example 8 differs from example 1 only in that nonapeptide-1 was added in an amount of 0.05wt%, and the other conditions were the same.
Example 9 preparation of skin Care compositions
Example 9 differs from example 1 only in that nonapeptide-1 was added in an amount of 0.1wt%, and the other conditions were the same.
EXAMPLE 10 preparation of skin Care composition
Example 10 differs from example 1 only in that the molecular weight of hyaluronic acid is different, the molecular weight of high molecular weight hyaluronic acid is 1200kDa, the molecular weight of low molecular weight hyaluronic acid is 700kDa, and the rest conditions are the same.
EXAMPLE 11 preparation of skin Care composition
Example 11 differs from example 1 only in that the molecular weight of hyaluronic acid is different, the molecular weight of high molecular weight hyaluronic acid is 1500kDa, the molecular weight of low molecular weight hyaluronic acid is 200kDa, and the rest conditions are the same.
EXAMPLE 12 preparation of skin Care compositions
Example 12 differs from example 1 only in that the molecular weight of the low molecular weight hyaluronic acid is different, the molecular weight of the low molecular weight hyaluronic acid is 50kDa, and the other conditions are the same.
EXAMPLE 13 preparation of skin Care compositions
Example 13 differs from example 1 only in that sodium hyaluronate with a molecular weight of 1200kDa was added in an amount of 0.067wt%, and sodium hyaluronate with a molecular weight of 500kDa was added in an amount of 0.033wt%, and the rest conditions were the same.
EXAMPLE 14 preparation of skin Care compositions
Example 14 differs from example 1 only in that sodium hyaluronate with a molecular weight of 1200kDa was added in an amount of 0.04wt% and sodium hyaluronate with a molecular weight of 500kDa was added in an amount of 0.06wt%, with the remaining conditions being the same.
Example 15 preparation of skin Care compositions
Example 15 differs from example 1 only in that sodium hyaluronate with a molecular weight of 1200kDa was added in an amount of 0.091wt%, and sodium hyaluronate with a molecular weight of 500kDa was added in an amount of 0.009wt%, and the remaining conditions were the same.
EXAMPLE 16 preparation of skin Care composition
Example 16 is different from example 1 only in that sodium hyaluronate with a molecular weight of 1200kDa was added in an amount of 0.1wt%, sodium hyaluronate with a molecular weight of 500kDa was not added, and the other conditions were the same.
EXAMPLE 17 preparation of skin Care compositions
Example 17 is different from example 1 only in that sodium hyaluronate with a molecular weight of 500kDa was added in an amount of 0.1wt%, sodium hyaluronate with a molecular weight of 1200kDa was not added, and the other conditions were the same.
Comparative example 1
Adding 0.1wt% of sodium hyaluronate with molecular weight of 1200kDa into water based on the total weight of the skin care composition, and fully stirring for 6h to obtain a uniform state, thereby obtaining the skin care composition.
Comparative example 2
Adding 0.1wt% of sodium hyaluronate with a molecular weight of 500kDa into water based on the total weight of the skin care composition, and fully stirring for 6h to a uniform state to obtain the skin care composition.
Comparative example 3
Adding 0.091wt% of sodium hyaluronate with the molecular weight of 1200kDa and 0.009wt% of sodium hyaluronate with the molecular weight of 500kDa into water, and fully stirring for 6h to obtain a uniform state, based on the total weight of the skin care composition, thereby obtaining the skin care composition.
Comparative example 4
Adding 0.05wt% of sodium hyaluronate with a molecular weight of 1200kDa and 0.05wt% of sodium hyaluronate with a molecular weight of 500kDa into water based on the total weight of the skin care composition, and fully stirring for 6h to obtain a uniform state, thereby obtaining the skin care composition.
Comparative example 5
Adding 0.05wt% of sodium hyaluronate with the molecular weight of 800kDa and 0.05wt% of sodium hyaluronate with the molecular weight of 50kDa into water, and fully stirring for 6h to obtain a uniform state, thereby obtaining the skin care composition.
Comparative example 6
Adding 0.005wt% of ergothioneine and 0.001wt% of nonapeptide-1 into water, and stirring for 6 hr to obtain skin care composition.
TABLE 2 comparison table of important parameters of examples and comparative examples
Test example 1 inflammatory factor test
23 healthy subjects were recruited, and 20min after washing the forearms, 19 square areas of 1.5cm × 1.5cm were selected on the inner side of the forearms, and the cuticle layer was continuously peeled off on the skin using an adhesive tape to establish a skin barrier loss model.
Sample use: the preparation is applied uniformly 1 time per day, 0.5mL each time, and is used continuously for 7 days.
The content of inflammatory factors in the skin stratum corneum is detected by a stratum corneum sampling test: each piece of D-Squame scotch tape was pressed continuously at the same site for 10 seconds using a pressure bar at the same pressure, and the sample was then taped and repeated 3 times. The first piece of D-Squame tape was discarded, with the 2 nd piece of scotch tape used to detect inflammation and was therefore tested. IL-1a, IL-1ra were measured using an ELISA assay, the greater the% change normalized to total protein content, the higher the level of inflammatory factors. The results of inflammatory factor assay for each of the examples and comparative examples are shown in Table 3.
TABLE 3 detection results of inflammatory factor of each composition of examples and comparative examples
As can be seen from table 3, the results of the subjects using the present skin care composition after skin barrier damage show that the change values of the examples are smaller than those of the comparative examples, wherein the minimum change value of example 1 indicates that sodium hyaluronate and ergothioneine in the skin composition prepared by the present application have a synergistic effect in improving inflammation, and the microenvironment for skin health can be effectively maintained.
Test example 2 trial test
In order to verify the use effect and the use feeling of the application, the applicant conducts trial observation on the population of the system, and the relevant conditions are as follows:
the trial population: the composition products of the examples and the comparative examples are respectively tried on 23 persons with mild and moderate acne pigmentation on the face, 23 persons with superficial scars, 23 persons after laser photon operation and the like.
The usage and dosage are as follows: 1 time a day, 1mL each time, trial for 7 days.
The therapeutic effect of the composition on acne pigmentation and superficial scar is detected by using a skin non-invasive instrument, the repairing effect of the conditions of erythema, edema, scorching heat and the like is observed by eye, and the testee fills a satisfaction questionnaire. The results are shown in Table 4.
TABLE 4 feedback Table of trial results for population of each of the examples and comparative examples
As can be seen from Table 4, the subject satisfaction was higher for example 1,2,4,7 than for comparative examples 1-3, where the overall satisfaction was the highest for example 7, indicating the best results. The comparison between the example 4 and the examples 1 and 2 shows that the skin care composition compounded by the high molecular weight sodium hyaluronate and the low molecular weight sodium hyaluronate has the using effect obviously superior to the case of independently using the high molecular weight sodium hyaluronate and the low molecular weight sodium hyaluronate. The comparison between the nonapeptide-1, the ergothioneine and the sodium hyaluronate shows that the nonapeptide-1, the ergothioneine and the sodium hyaluronate have a synergistic effect, so that the acne pigmentation state of the skin of a subject is greatly improved, the healthy ecological environment of the skin is improved, and the subject has higher satisfaction.
Test example 3 human body test
In order to verify that the repair time after the laser photon operation can be effectively shortened, the applicant conducts systematic crowd trial observation, and relevant conditions are as follows:
the trial population: 21 patients after laser photon surgery, the compositions of examples 1,2,4,7 and comparative examples 1-3 were used.
The usage and dosage are as follows: 1 time a day, 1mL each time, trial for 7 days.
The results are shown in Table 5.
TABLE 5 compositions of the examples and comparative examples for post-laser photon repair time
| Group of | Time to regress/day |
| Example 1 | 3 |
| Example 15 | 5 |
| Example 16 | 5 |
| Comparative example 1 | 8 |
| Comparative example 2 | 7 |
| Comparative example 4 | 6 |
| Comparative example 6 | 8 |
As can be seen from Table 5, the subjects in example 1,2,4,7 all had lower repair times than comparative examples 1-3, where example 7 had the shortest post-operative repair time. As can be seen from the comparison of example 7 with comparative examples 1,2 and 3, when nonapeptide-1 and ergothioneine are used together with hyaluronic acid or a salt thereof, the synergistic effect is achieved, and the repair time after the laser photon operation is greatly shortened.
Although the present disclosure has been described with reference to particular embodiments, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the spirit and scope of the present disclosure, and the scope of the present disclosure should be limited only by the terms of the appended claims.
Claims (7)
1. A skin care composition characterized in that said skin care composition comprises: hyaluronic acid or its salt, ergothioneine, and nonapeptide-1.
2. The skin care composition of claim 1,
the hyaluronic acid or the salt thereof is composed of high molecular weight hyaluronic acid or the salt thereof, and low molecular weight hyaluronic acid or the salt thereof,
wherein the molecular weight of the high molecular weight hyaluronic acid or salt thereof is 1000-1500kDa, and the molecular weight of the low molecular weight hyaluronic acid or salt thereof is 200-700kDa.
3. The skin care composition according to claim 2, wherein the mass ratio of the high molecular weight hyaluronic acid or salt thereof to the low molecular weight hyaluronic acid or salt thereof is 1.
4. The skin care composition according to claim 1, wherein the mass ratio of hyaluronic acid or a salt thereof, ergothioneine, nonapeptide-1 is (0.05-1.0): (0.001-0.3): (0.01-0.1).
5. The skin care composition according to claim 1,
0.05-1.0wt% of hyaluronic acid or salt thereof, 0.001-0.3 wt% of ergot sulfur, and 0.01-0.1 wt% of nonapeptide-1, based on the total weight of the skin care composition;
preferably, the hyaluronic acid or the salt thereof is 0.1-0.5wt%, the ergot sulfur is 0.005-0.2 wt%, and the nonapeptide-1 is 0.01-0.05 wt%.
6. A skin care product comprising the skin care composition of any one of claims 1-5.
7. Use of the skin care composition of any one of claims 1-5 or the skin care product of claim 6 in the manufacture of a medicament or cosmetic for anti-inflammation, reducing pigmentation and superficial scarring.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211078137.XA CN115814054A (en) | 2022-09-05 | 2022-09-05 | Skin care composition, skin care product and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211078137.XA CN115814054A (en) | 2022-09-05 | 2022-09-05 | Skin care composition, skin care product and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115814054A true CN115814054A (en) | 2023-03-21 |
Family
ID=85523381
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211078137.XA Pending CN115814054A (en) | 2022-09-05 | 2022-09-05 | Skin care composition, skin care product and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115814054A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111568918A (en) * | 2020-06-24 | 2020-08-25 | 华熙生物科技股份有限公司 | Gel composition for treating inflammatory acne and preparation method thereof |
| CN111658585A (en) * | 2020-06-24 | 2020-09-15 | 珠海美逸生物科技有限公司 | Whitening and spot-fading composition and preparation method thereof |
| CN114642606A (en) * | 2022-04-18 | 2022-06-21 | 山东禾三千医疗科技有限公司 | Composition with skin barrier repair function and preparation method and application thereof |
-
2022
- 2022-09-05 CN CN202211078137.XA patent/CN115814054A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111568918A (en) * | 2020-06-24 | 2020-08-25 | 华熙生物科技股份有限公司 | Gel composition for treating inflammatory acne and preparation method thereof |
| CN111658585A (en) * | 2020-06-24 | 2020-09-15 | 珠海美逸生物科技有限公司 | Whitening and spot-fading composition and preparation method thereof |
| CN114642606A (en) * | 2022-04-18 | 2022-06-21 | 山东禾三千医疗科技有限公司 | Composition with skin barrier repair function and preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108685759B (en) | Composition of hyaluronic acid substance and tetrahydropyrimidine substance | |
| KR102212023B1 (en) | Water-soluble hyaluronic acid gel and method for producing same | |
| US9101538B2 (en) | Injectable amino-acid composition | |
| CN109549893B (en) | Composition and essence milk with blue light pollution resistance and repair effects and preparation method of essence milk | |
| WO2006094193A3 (en) | Compositions and methods for topical application and transdermal delivery of an oligopeptide | |
| CN108686255B (en) | Biological dressing for preventing scar formation and preparation method thereof | |
| CN110123695B (en) | Cell energy restoration composition | |
| CN114903981A (en) | Wound repair formula containing recombinant type III collagen | |
| CN107951769A (en) | Anti-aging face cream and preparation method and application thereof | |
| KR20150120426A (en) | Cosmetic composition containing a brown alga extract, a yeast extract and ascorbic acid | |
| CN104887542B (en) | A cosmetic composition | |
| CN107296764A (en) | Cream and preparation method thereof | |
| EP3932436A1 (en) | Medical adhesive, and manufacturing method therefor and use thereof | |
| CN114010584A (en) | Antibacterial wound repair gel and preparation method thereof | |
| CN109330912A (en) | Beautifying skin remediation composition and facial mask | |
| CN111888314A (en) | Essence containing copper peptide and preparation method thereof | |
| CN107412745A (en) | Complex polypeptide liquid and preparation method and application | |
| CN115814054A (en) | Skin care composition, skin care product and application thereof | |
| CN104224676A (en) | Spirulina anti-wrinkle anti-aging facial mask | |
| CN108578297A (en) | A kind of compounding moisturizing sun cream and preparation method thereof | |
| RU2577950C1 (en) | Method of stimulating healing dermal burns | |
| KR20140145274A (en) | Composition for skin moisturizing containing oxygen dissolving water with a polymer composition | |
| CN108686260B (en) | Preparation method of compound scar-proof emulsion biological dressing | |
| CN111870558A (en) | Composition for inhibiting hyaluronidase activity and skin care product | |
| CN114432179A (en) | Formula and preparation method of chitosan water replenishing repair essence cosmetic |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |